Skip to content

Effect of Atorvastatin and CoQ10 on stroke

Evaluating the protective effects of Atorvastatin compared with Atorvastatin- Coenzyme Q10 co-administration on level of GFAP in patients with stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017041731773N1
Enrollment
60
Registered
2017-06-21
Start date
2017-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Atorvastatin = 40 mg/day.oral, Coadministration with CoQ10= 300 mg/day Three times a day. 30 days. oral. Intervention 2: Atorvastatin= 40 mg/day,daily 30 days, oral.
Treatment - Drugs
Atorvastatin = 40 mg/day.oral, Coadministration with CoQ10= 300 mg/day Three times a day. 30 days. oral.
Atorvastatin= 40 mg/day,daily 30 days, oral

Sponsors

Vice chancellor for research, Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (patients with ischemic stroke involving the middle cerebral artery, confirmed by computed tomography scanning and clinical symptoms; range of age 50-70 years; not to receive statins continuously before entering the study; not to receive antioxidants (such as vitamin C and E) constantly; not to receive anti-inflammatory drugs (steroids, nonsteroidal anti-inflammatory) constantly; not affected by AIDS and neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis); no loss of consciousness level due to any reason except stroke (such as shock, alcohol consumption or intoxication); non-pregnancy; non-epilepsy; patient`s consent).Exclusion criteria: (patient's death during the study; lack of patient`s availability to follow-up; no tendency to attend in next follow-up).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Degree of disability. Timepoint: Admission- After 30 day. Method of measurement: Modified Rankin Scale (MRS).;Glial fibrillary acidic protein(GFAP). Timepoint: admission- 72 houre-after 30 day. Method of measurement: eliza kit.;Cognitive performance. Timepoint: admission- 72 houre-after 30 day. Method of measurement: Mini-Mental State Examination(MMSE).;Motor function and verbal. Timepoint: admission- 72 houre-after 30 day. Method of measurement: National Institutes of Health Stroke Scale(NIHSS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Simani

Shahid Beheshti University of Medical Sciences

l.simani90@sbmu.ac.ir+98 21 5102 5582

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026